VANCOUVER, Oct. 9 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to announce a series of positive experiments investigating the systemic
bioavailability of amphotericin B following oral administration. iCo-009 is
iCo's oral formulation of Amphotericin B, a broad spectrum antifungal drug
which currently can only be delivered by intravenous (IV) infusion. Results
indicate that oral administration of iCo-009 results in blood levels that are
comparable to a known IV Amphotericin B product currently on the market.
